Table 1.

Summary of clinical studies in NSCLC with driver gene mutations.

Gene alteration	Study	Therapy	n	ORR (%)	DCR (%)	PFS (m)	Reference
EGFR	FURLONG	Furmonertinib	178	89.0	84.0	20.8	[4]
		Gefitinib	179	96.0	93.0	11.1
	AENEAS	Aumolertinib	214	73.8	72.1	19.3	[5]
		Gefitinib	215	93.0	96.7	9.9
	NCT02108964	Nazartinib	45	69.0	91.0	18.0	–
	AfaBev‐CS	Afatinib + bevacizumab	49	–	–	16.3	[6]
		Afatinib	50	–	–	16.1
	WJOG9717L	Osimertinib + bevacizumab	61	–	–	22.1	[7]
		Osimertinib	61	–	–	20.2
		Osimertinib + PEM + carboplatin	33	90.9	97.0	–	[8]
	CHRYSALIS	Amivantamab + lazertinib	20	100.0	100.0	NE	[9]
EGFR TKI resistance	U31402‐A‐U102	HER3‐DXd	44	39.0	68.0	8.2	[10]
	SAVANNAH	Osimertinib+savolitinib (IHC50 + and/or FISH5+)	193	32.0	61.0	5.3	[11]
		Osimertinib+savolitinib (IHC90 + and/or FISH10+)	108	49.0	74.0	7.1
	NCT02099058	Osimertinib + Teliso − V	25	58.0	–	–	[12]
		Osimertinib + Teliso − V 1.9 mg/kg	18	67.0	–	–
	ORIENT‐31	Sintilimab + IBI305 + platinum‐based chemotherapy	158	48.1	86.1	7.2	[13]
		Sintilimab + platinum‐based chemotherapy	158	34.8	81.6	5.5
		Platinum‐based chemotherapy	160	29.4	75.6	4.3
EGFR Ex20ins	WU‐KONG1 WU‐KONG2 WU‐KONG6	Sunvozertinib	84	52.4	–	–	[14]
	POSITION20	High dose osimertinib	25	28.0	–	6.8	[15]
EGFR G719X, S768I and L861Q mutations	ARTICUNO	Osimertinib (G719X)	19	50.0	89.0	11.0	[16]
		Osimertinib (L861X)	15	50.0	86.0	9.0
		Osimertinib (S768I)	11	55.0	91.0	17.0
ALK	CROWN Asian	Lorlatinib	59	78.0	–	NR	[17]
		Crizotinib	61	57.4	–	11.1
	J‐ALEX	Alectinib	103	–	–	34.1	[18]
		Crizotinib	104	–	–	10.2
	NCT03909971	lorlatinib (cohort 1: previous crizotinib)	67	70.1	82.0	NR	[19]
		lorlatinib (cohort 2: one ALK TKI other than crizotinib [±prior crizotinib])	42	47.6	61.9	5.6
MET14 exon skipping mutation	NCT02897479	Savolitinib	70	47.1	81.4	6.9	[20]
	VISION	Tepotinib (cohort C)	161	54.7	80.1	13.8	[21]
	GLORY	SCC244	73	60.9	82.6	7.6	[22]
HER2 mutation	DESTINY‐Lung02	T‐DXd 5.4 mg/kg Q3W	52	53.8	90.4	–	[23]
		T‐DXd 6.4 mg/kg Q3W	28	42.9	92.9	–
BRAF V600 mutation	NCT04452877	Dabrafenib + trametinib	18	75	–	NR	[24]
RET fusion	ARROW	Pralsetinib (prior platinum treatment)	130	82	–	16.4	[25]
		Pralsetinib (no prior systemic treatment)	107	83	–	12.6
	LIBRETTO‐001	Selpercatinib (treatment‐naïve)	69	84.1	–	22.0	[26]
		Selpercatinib (previous platinum chemotherapy)	247	61.1	–	24.9
	LIBRETTO‐321	Selpercatinib (treatment‐naïve)	8	87.5	–	NR	[27]
		Selpercatinib (pretreated)	18	61.1	–	NR
KRAS	CodeBreaK 200	Sotorasib	169	28.1	82.5	5.6	[28]
		Docetaxel	151	13.2	60.3	4.5
	KRYSTAL‐1	MRTX849	112	43	80	6.5	[29]
ROS1 fusion	EUCROSS	Crizotinib	34	70	90	19.4	[30]
	STARTRK‐1, STARTRK2, ALKA‐372‐001 (EudraCT 2012‐000148‐8)	Entrectinib	172	67.4	86.7	16.8	[31]
		Entrectinib (first‐line cohort)	67	68.7	79.1	17.7
	NCT03972189	Unecritinib	111	78.4	87.4	15.6	[32]
NTRK gene	NCT02576431 NCT02122913	Larotrectinib	26	83	100	NR	[33]
Fusion in a pan‐cancer setting	STARTRK‐1, STARTRK2, ALKA‐372‐001 (EudraCT 2012‐000148‐8)	EntrectinibA	31	64.5	–	–	[34]
	STARTRK 2	Entrectinib (mainland China, Hong Kong, Taiwan)	21	81	85.8	30.3	[35]

Abbreviations: ALK, anaplastic lymphoma kinase; DSR, disease control rate; EGFR, epidermal growth factor receptor; NSCLC, nonsmall cell lung cancer; ORR, objective response rate; PFS, progression‐free survival; TKI, tyrosine kinase inhibitor.